From Disease Staging to Treatment Strategy: Multidisciplinary Approaches in Newly Diagnosed Anal Canal Carcinoma
Panelists discuss how diagnosis and staging of anal cancer involves digital rectal examination, high-resolution anoscopy with biopsy, p16 testing, and pelvic MRI for accurate staging, while considering patient factors like HIV status, treatment adherence capability, and comorbidities when planning curative intent therapy.
Diagnosis and Staging Approaches
The diagnostic workup for anal cancer involves comprehensive clinical evaluation including digital rectal examination, physical examination for palpable lymph nodes, and complete assessment of regional anatomy. Confirmation requires high-resolution anoscopy with biopsy, testing for p16 (HPV surrogate marker), and HIV testing when indicated. The standard imaging protocol includes PET-CT and chest CT to exclude metastatic disease, with pelvic MRI increasingly utilized for accurate T and N staging.
Treatment considerations must account for various patient and disease characteristics, particularly in underserved populations where adherence to treatment regimens may be challenging. Factors influencing treatment approach include the patient's ability to maintain radiation visits, comorbidities affecting systemic therapy tolerance, and whether patients can receive port placement for 5-FU-based regimens or reliably take oral capecitabine throughout treatment.
Multidisciplinary care coordination is essential, involving colorectal surgeons, gastroenterologists, and specialized HIV clinics for early detection. The discussion emphasizes the importance of distinguishing anal squamous cell carcinoma from rectal adenocarcinoma through proper immunohistochemistry, as misdiagnosis can lead to inappropriate treatment approaches. Early symptom management, including pain control and prevention of constipation, is crucial for maintaining treatment intensity and preventing emergency department visits.
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
